The present invention provides a compound represented by the following formula (I):
wherein:
Ring A represents an optionally substituted piperazine ring, an optionally substituted morpholine ring, or an optionally substituted homopiperazine ring;
R
1
and R
2
are the same or different from each other, and represent a hydrogen atom or optionally substituted lower alkyl;
R
3
and R
4
are the same or different from each other, and represent a hydrogen atom or halogenated or non-halogenated lower alkyl;
R
5
to R
7
are the same or different from each other, and represent a hydrogen atom, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkoxy, optionally substituted cycloalkyl, optionally substituted aryl, an optionally substituted aromatic heterocyclic ring, optionally substituted amino, or acyl; and
represents a single bond or double bond, or a salt thereof.
Formaldehyde-Extruding Homolytic Aromatic Substitution via C→O Transposition: Selective ‘Traceless-Linker’ access to Congested Biaryl Bonds
作者:Pabhon Poonpatana、Gabriel dos Passos Gomes、Thomas Hurrle、Kimhoa Chardon、Stefan Bräse、Kye-Simeon Masters、Igor Alabugin
DOI:10.1002/chem.201700085
日期:2017.7.6
A new, selective way to form C−C bonds has been developed. In this report, we disclose the homolytic aromaticsubstitution via C→O transposition coupled with the elimination of formaldehyde (as a traceless linker). Computational analysis indicates the selectivity can be tuned by sterics in the starting materials following an ipso‐attack that leads to the C→O transposition.
HETEROCYCLIC CARBOXYLIC ACIDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE
申请人:Boehringer Ingelheim International GmbH
公开号:US20160024059A1
公开(公告)日:2016-01-28
The present invention relates to compounds of formula I:
and pharmaceutically acceptable salts thereof, wherein R
1
, R
2
, R
3
, R
5
, R
6
, R
7
, R
8
, R
9
, B, V, W, X, Y, Z and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
[EN] GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES<br/>[FR] ANTAGONISTE DES RECEPTEURS DU GLUCAGON, PREPARATION ET UTILISATIONS THERAPEUTIQUES
申请人:LILLY CO ELI
公开号:WO2005123668A1
公开(公告)日:2005-12-29
The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.
Selectivity enhancement of aromatic halogenation reactions at the micellar interface: effect of highly ionic media
作者:Bhupesh S. Samant、Sunil S. Bhagwat
DOI:10.1007/s00706-011-0677-1
日期:2012.7
media in order to observe the effect on regioselectivity and conversion of the reaction. The addition of surfactant causes a change in the chemical shifts of the aromatic proton resonance of phenol which proves the orientation of the aromatic compound on the micellar surface. However, increase in ionic strength of the reaction media affects the selectivity of reaction by disturbing this spatial orientation